Health News Archive - May 02, 2011
Prescriptions for narcotics often contain too much medication per dose.
FRAZER, Pa., May 2, 2011 /PRNewswire/ -- Cephalon, Inc. (Nasdaq: CEPH) is scheduled to release its first quarter 2011 results via PR Newswire after the market close (approximately 4:10 p.m.) on Tuesday, May 3, 2011.
ATLANTA, May 2, 2011 /PRNewswire/ -- To commence National Arthritis Awareness Month in May, the Arthritis Foundation is calling on Americans to get moving. As part of the Let's Move Together campaign, the Arthritis Foundation is hosting more than 200 Arthritis Walk events across the country.
FRESNO, Calif., May 2, 2011 /PRNewswire/ -- The month of May ushers in plans for family vacations, increased time outdoors and even busier calendars filled with activities.
SOUTHBOROUGH, Mass., May 2, 2011 /PRNewswire/ -- SynapDx Corporation announced today that is has obtained an exclusive world-wide license to technology from Children's Hospital Boston to accelerate the Company's development of blood-based tests to enable the early detection of Autism Spectrum Disorders.
WASHINGTON, May 2, 2011 /PRNewswire/ -- The Hospice Foundation of America has developed "Alzheimer's Disease and Hospice Care," a free online webinar that examines how hospice care can support patients and families coping with end-stage Alzheimer's disease and other dementias. More than 5 million people in the U.S.
AURORA, Ohio, May 2, 2011 /PRNewswire-USNewswire/ -- As a mother trying to determine why her child was struggling with reading and learning, Robin Benoit found it very difficult to locate answers.
BETHLEHEM, Pa., OBERWIL, Switzerland and MUNICH, May 2, 2011 /PRNewswire/ -- Saladax Biomedical, Inc., a privately held company developing and commercializing novel diagnostic assays to achieve the promise of personalized medicine for new and existing therapeutics, announced today the formation of its European commercialization team to expand its European presence. Reporting to Adrienne Choma, Esq., Saladax VP, Marketing and Sales, members of Saladax's European commercialization team include: Ursula Sonnenschein, Ph.D.
AUSTIN, TEXAS, May 2 /PRNewswire/ - Affinium Pharmaceuticals announced today the results of a new multiple ascending dose Phase I study of its novel, selective-spectrum, anti-staphylococcal agent, AFN-1252 in a novel oral formulation. The study examined the tolerability, safety and pharmacokinetics of immediate release tablets of AFN-1252.
TAMPA, Florida, May 2, 2011 /PRNewswire-FirstCall/ -- Leading drug database provider, Elsevier/Gold Standard, (http://www.goldstandard.com/) announced today that eHealthObjects, an innovative healthcare solutions company, which specializes in delivering healthcare technology products, solutions and platforms that can seamlessly be integrated with other systems, has chosen Alchemy as its drug database. Alchemy is a complete drug database best known for its intelligent screening tools, which eliminate irrelevant and unnecessary alerts.